2.47

2.87% 0.08

Zentalis Pharmaceuticals Inc (ZNTL)

Overview News Price History Option Chain Financials Why ZNTL Down? Discussions Forecast

Zentalis Pharmaceuticals Inc stock is traded at $2.47, with a volume of 205.09K. It is up +2.87% in the last 24 hours and down -2.05% over the past month. Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.

Previous Close:

$2.39

Open:

$2.35

24h Volume:

205.09K

Relative Volume:

0.17

Market Cap:

$159.93M

Revenue:

Net Income/Loss:

$-292.19M

P/E Ratio:

-0.5441

EPS:

-4.54

Net Cash Flow:

$-208.41M

1W Performance:

+0.35%

1M Performance:

-2.05%

6M Performance:

+42.94%

1Y Performance:

+18.77%

1-Day Range:

$2.35

$2.495

1-Week Range:

$2.35

$2.61

52-Week Range:

$1.01

$3.95

Zentalis Pharmaceuticals Inc Stock (ZNTL) Company Profile

Name

Zentalis Pharmaceuticals Inc

Sector

Healthcare (1114)

Industry

Biotechnology (620)

Phone

(858) 263-4333

Address

10275 SCIENCE CENTER DRIVE, SAN DIEGO, NY

Employee

166

Twitter

@ZentalisP

Next Earnings Date

2025-03-26

Latest SEC Filings

ZNTL's Discussions on Twitter

Compare ZNTL vs VRTX, REGN, ARGX, ALNY, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
ZNTL Zentalis Pharmaceuticals Inc	2.47	154.75M	0	-292.19M	-208.41M	-4.54
VRTX Vertex Pharmaceuticals Inc	490.53	126.21B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	786.52	82.64B	14.34B	4.50B	3.77B	41.56
ARGX Argen X Se Adr	760.69	47.46B	3.06B	1.28B	447.35M	19.67
ALNY Alnylam Pharmaceuticals Inc	327.50	44.15B	3.71B	313.75M	465.38M	2.2571
ONC Beone Medicines Ltd Adr	312.07	35.08B	4.98B	69.60M	525.67M	0.5198

Zentalis Pharmaceuticals Inc Stock (ZNTL) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Aug-12-24	Upgrade	Wedbush	Underperform → Neutral
Jun-20-24	Downgrade	UBS	Buy → Neutral
Jun-18-24	Downgrade	Jefferies	Buy → Hold
Jun-18-24	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Jun-18-24	Downgrade	Wedbush	Neutral → Underperform
Jun-18-24	Downgrade	Wells Fargo	Overweight → Equal Weight
Nov-08-23	Downgrade	Wedbush	Outperform → Neutral
Nov-07-23	Downgrade	Leerink Partners	Outperform → Market Perform
Jul-12-22	Initiated	Cowen	Outperform
Apr-06-22	Initiated	Wells Fargo	Overweight
Oct-07-21	Resumed	Jefferies	Buy
Sep-30-21	Initiated	Stifel	Buy
Sep-29-21	Initiated	Oppenheimer	Outperform
May-21-21	Initiated	UBS	Buy
Jan-20-21	Initiated	Wedbush	Outperform
Sep-29-20	Initiated	Cantor Fitzgerald	Overweight
Aug-27-20	Initiated	H.C. Wainwright	Buy
Apr-28-20	Initiated	Guggenheim	Buy
Apr-28-20	Initiated	Jefferies	Buy
Apr-28-20	Initiated	Morgan Stanley	Overweight
Apr-28-20	Initiated	SVB Leerink	Outperform

View All

Zentalis Pharmaceuticals Inc Stock (ZNTL) Latest News

Feb 24, 2026

Loss Report: Is Alector Inc a strong growth stock2025 Macro Impact & AI Driven Price Forecasts - baoquankhu1.vn

Feb 24, 2026

Feb 23, 2026

ZNTL Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan

Feb 23, 2026

Feb 22, 2026

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Receives Average Rating of "Hold" from Analysts - MarketBeat

Feb 22, 2026

Feb 20, 2026

Is Zentalis Pharmaceuticals Inc. likely to announce a buybackMarket Activity Recap & Trade Opportunity Analysis - mfd.ru

Feb 20, 2026

Rate Cut: Can Zentalis Pharmaceuticals Inc. expand its profit marginsBear Alert & Proven Capital Preservation Methods - mfd.ru

Feb 20, 2026

Feb 19, 2026

Layoff Watch: Can Zentalis Pharmaceuticals Inc keep up with sector leadersMarket Performance Summary & Stepwise Entry and Exit Trade Signals - baoquankhu1.vn

Feb 19, 2026

Feb 18, 2026

Zentalis Pharmaceuticals to Participate in Upcoming Investor Conferences - Bitget

Feb 18, 2026

Aug PostEarnings: Is ASTS stock heavily shortedJuly 2025 PreEarnings & Weekly High Conviction Trade Ideas - baoquankhu1.vn

Feb 18, 2026

Feb 17, 2026

Zentalis Pharmaceuticals Details Azenosertib Path to PROC Approval, DENALI Dose Pick Coming Soon - Defense World

Feb 17, 2026

Feb 16, 2026

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Short Interest Update - MarketBeat

Feb 16, 2026

Feb 15, 2026

Is Zentalis Pharmaceuticals Inc. forming a double bottomTrade Risk Assessment & Stepwise Swing Trade Plans - mfd.ru

Feb 15, 2026

Feb 14, 2026

Can Zentalis Pharmaceuticals Inc. stock sustain institutional interestDollar Strength & Daily Entry Point Trade Alerts - mfd.ru

Feb 14, 2026

Feb 13, 2026

Is Zentalis Pharmaceuticals Inc. currently under institutional pressure2025 Volume Leaders & Risk Controlled Daily Trade Plans - mfd.ru

Feb 13, 2026

Don't Ignore The Insider Selling In Zentalis Pharmaceuticals - simplywall.st

Feb 13, 2026

Have Zentalis Pharmaceuticals Insiders Been Selling Stock? - 富途牛牛

Feb 13, 2026

Feb 10, 2026

Vincent Vultaggio Sells 29,951 Shares of Zentalis Pharmaceuticals (NASDAQ:ZNTL) Stock - MarketBeat

Feb 10, 2026

Zentalis Pharmaceuticals PAO sells shares worth $97,556 By Investing.com - Investing.com Canada

Feb 10, 2026

Zentalis Pharma CMO Bruns sells $7998 in stock By Investing.com - Investing.com Canada

Feb 10, 2026

Zentalis Pharma CEO Eastland sells $21k in shares By Investing.com - Investing.com Canada

Feb 10, 2026

Zentalis Pharmaceuticals PAO sells shares worth $97,556 - Investing.com

Feb 10, 2026

Will Zentalis Pharmaceuticals Inc. be affected by tariffsJuly 2025 Reactions & Fast Exit Strategy with Risk Control - mfd.ru

Feb 10, 2026